Evidence map›Paper›PMID 37659140›Full record

ArticleJournal of diabetes and its complications2023

Increased intracellular miR-142 in adults with Type 1 diabetes.

Li Huang, Andrzej S Januszewski, Yusuke Takahashi, David N O'Neal, Jian-Xing Ma, Alicia J Jenkins

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes and its complications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Li HuangDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Ophthalmology, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.
Andrzej S JanuszewskiNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Deptartment of Medicine, University of Melbourne, Melbourne, VIC, Australia; Sydney Pharmacy School, University of Sydney, Sydney, NSW, Australia.
Yusuke TakahashiDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Deptartment of Biochemistry, Wake Forest University, School of Medicine, Winton-Salem, NC, USA. Electronic address: ytakahas@wakehealth.edu.
David N O'NealNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Deptartment of Medicine, University of Melbourne, Melbourne, VIC, Australia; Deptartment of Biochemistry, Wake Forest University, School of Medicine, Winton-Salem, NC, USA.
Jian-Xing MaDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Deptartment of Biochemistry, Wake Forest University, School of Medicine, Winton-Salem, NC, USA; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Alicia J JenkinsNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Deptartment of Medicine, University of Melbourne, Melbourne, VIC, Australia; Deptartment of Endocrinology and Diabetes, St. Vincent's Hospital, Melbourne, VIC, Australia; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. Electronic address: alicia.jenkins@baker.edu.au.
University of Melbourne · AUBaker Heart and Diabetes Institute · AUFujian Medical University · CNUniversity of Sydney · AUWake Forest University · US

Funding

A new pathogenic mechanism for diabetic retinopathyR01EY019309 · NEI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Jian-Xing Jay Ma · 2009 to 2026
$6.1M
STUDIES OF RPE65R01EY012231 · NEI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MA, JIAN-XING, MOISEYEV, GENNADIY · 1998 to 2021
$5.7M
Sustained release of fenofibrate for the treatment of diabetic retinopathyR01EY033477 · NEI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Jian-Xing Jay Ma, QINGGUO XU · 2022 to 2026
$2.7M
A Novel Pathogenic Pathway for Diabetic KeratopathyR01EY028949 · NEI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Dimitrios Karamichos, Jian-Xing Jay Ma · 2018 to 2026
$2.2M
cGAS-STING signaling in diabetic retinopathyR01EY033330 · NEI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Jian-Xing Jay Ma, Yusuke Takahashi · 2022 to 2026
$1.9M
Dysregulation of Wnt signaling in subretinal fibrosis in AMDR01EY032931 · NEI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI TAKAHASHI, YUSUKE · 2021 to 2025
$1.9M
Studies of retinyl ester hydrolase in the visual cycleR01EY032930 · NEI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MA, JIAN-XING JAY, MOISEYEV, GENNADIY · 2021 to 2025
$1.9M
NEI NIH HHS R01 EY012231NEI NIH HHS R01 EY019309NEI NIH HHS R01 EY028949NEI NIH HHS R01 EY032930NEI NIH HHS R01 EY032931NEI NIH HHS R01 EY033330NEI NIH HHS R01 EY033477
6 · The paper itself

Abstract

microRNAs (miRs), including miR-142, modulate gene expression and processes implicated in vascular damage and may serve as therapeutic targets and agents, including in Type 1 diabetes (T1D). The project aimed to assess whether miR-142 levels differ between people with and without T1D, and to analyse miR-142 associations with cardiovascular (CVD) risk factors. Intracellular miRs were isolated from whole blood cell pellets using TRIzol-based methodology. In a cross-sectional study in 102 adults cellular miR-142 levels were significantly higher (on unadjusted and adjusted analyses) in 69 adults with T1D relative to 33 non-diabetic subjects: mean ± SD, 3.53 ± 3.66 vs. 1.25 ± 0.78, p < 0.0002, but were not related to HbA1c levels. Further miR-142 research, including longitudinal and intervention studies and basic science are of interest. miR-142 may be valuable in clinical practice for predicting health and as a treatment target.

Indexed as

Diabetes Mellitus, Type 1MicroRNAsAdultBiomarkersCardiovascular DiseasesCase-Control StudiesCross-Sectional StudiesDiabetic AngiopathiesFemaleGlycated HemoglobinHumansMaleMiddle AgedRisk FactorsBiomarkersGlycated HemoglobinMicroRNAsMIRN142 microRNA, humanmicrovascular complicationsmiR-142Type 1 diabetes

Identifiers

PMID37659140
PMCPMC10592019
OpenAlexW4386160789

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.